- Home
- KROS vs GAIN Comparison
KROS vs GAIN Comparison
Compare KROS & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KROS | GAIN |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.9M | 551.1M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | KROS | GAIN |
|---|---|---|
| Price | $17.73 | $13.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $22.20 | $14.50 |
| AVG Volume (30 Days) | ★ 597.1K | 152.3K |
| Earning Date | 02-25-2026 | 02-11-2026 |
| Dividend Yield | N/A | ★ 15.73% |
| EPS Growth | N/A | ★ 135.24 |
| EPS | 1.57 | ★ 2.49 |
| Revenue | ★ $246,718,000.00 | $97,742,000.00 |
| Revenue This Year | $6,924.79 | $8.12 |
| Revenue Next Year | N/A | $5.05 |
| P/E Ratio | $11.38 | ★ $5.61 |
| Revenue Growth | ★ 37798.31 | 6.86 |
| 52 Week Low | $9.12 | $11.42 |
| 52 Week High | $22.55 | $15.34 |
Technical Indicators
Market Signals| Indicator | KROS | GAIN |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 50.96 |
| Support Level | $19.76 | $13.77 |
| Resistance Level | $21.76 | $14.12 |
| Average True Range (ATR) | 0.81 | 0.19 |
| MACD | -0.54 | 0.01 |
| Stochastic Oscillator | 5.18 | 60.00 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.